Literature DB >> 2196520

Side effects of methylphenidate in children with attention deficit hyperactivity disorder: a systemic, placebo-controlled evaluation.

R A Barkley1, M B McMurray, C S Edelbrock, K Robbins.   

Abstract

The frequency and severity of 17 side effects presumably associated with stimulant medication were assessed during a rigorous, triple-blind, placebo-controlled, crossover evaluation of methylphenidate, 0.3 and 0.5 mg/kg twice a day, in 83 children with attention deficit hyperactivity disorder. Side effects were rated by parents and teachers at the end of each weekly drug condition. Three children (3.6%) had side effects that were sufficiently serious to warrant immediate discontinuation of medication. Parent ratings indicated that only the side effects of decreased appetite, insomnia, stomachaches, and headaches increased significantly in frequency and severity during the two active medication doses as compared with the placebo condition. Fewer than half of the children experienced these side effects and among those who did, ratings of mean severity remained in the mild range. Teacher ratings showed little change over drug conditions, except on ratings of staring, sadness, and anxiety, which declined with increasing dose of medication. Parent ratings indicated that only the side effects of decreased appetite, insomnia, stomachaches, and headaches increased significantly in frequency and severity during the two active medication doses as compared with the placebo condition. Fewer than half of the children experienced these side effects and among those who did, ratings of mean severity remained in the mild range. Teacher ratings showed little change over drug conditions, except on ratings of staring, sadness, and anxiety, which declined with increasing dose of medication. Surprisingly, a high frequency of these behavior side effects were reported during the placebo condition. Stimulant medication within this therapeutic range, therefore, results in few, generally mild side effects.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2196520

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  86 in total

1.  Evidence and belief in attention deficit hyperactivity disorder. Narrow focus of editorial was disappointing.

Authors:  S Timimi
Journal:  BMJ       Date:  2001-03-03

Review 2.  Pharmacological treatment of depression in children and adolescents.

Authors:  R L Findling; M D Reed; J L Blumer
Journal:  Paediatr Drugs       Date:  1999 Jul-Sep       Impact factor: 3.022

Review 3.  ADHD treatments, sleep, and sleep problems: complex associations.

Authors:  Mark A Stein; Margaret Weiss; Laura Hlavaty
Journal:  Neurotherapeutics       Date:  2012-07       Impact factor: 7.620

Review 4.  Understanding attention-deficit/hyperactivity disorder from childhood to adulthood.

Authors:  Timothy E Wilens; Thomas J Spencer
Journal:  Postgrad Med       Date:  2010-09       Impact factor: 3.840

5.  Detecting treatment emergent adverse events in clinical trials : a comparison of spontaneously reported and solicited collection methods.

Authors:  Joachim F Wernicke; Douglas Faries; Denái Milton; Karen Weyrauch
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

6.  Comparison of the clinical efficacy of twice-daily Ritalin and once-daily Equasym XL with placebo in children with Attention Deficit/Hyperactivity Disorder.

Authors:  Robert L Findling; Declan Quinn; Simon J Hatch; Sara J Cameron; Heleen H DeCory; Michael McDowell
Journal:  Eur Child Adolesc Psychiatry       Date:  2006-06-21       Impact factor: 4.785

7.  Effects of acute nicotine administration on behavioral inhibition in adolescents with attention-deficit/hyperactivity disorder.

Authors:  Alexandra S Potter; Paul A Newhouse
Journal:  Psychopharmacology (Berl)       Date:  2004-04-09       Impact factor: 4.530

8.  Dopamine transporter genotype and stimulant dose-response in youth with attention-deficit/hyperactivity disorder.

Authors:  Mark A Stein; Irwin Waldman; Jeffrey Newcorn; Jeffrey Bishop; Rick Kittles; Edwin H Cook
Journal:  J Child Adolesc Psychopharmacol       Date:  2014-05-09       Impact factor: 2.576

Review 9.  Non-stimulant medications in the treatment of ADHD.

Authors:  Tobias Banaschewski; Veit Roessner; Ralf W Dittmann; Paramala Janardhanan Santosh; Aribert Rothenberger
Journal:  Eur Child Adolesc Psychiatry       Date:  2004       Impact factor: 4.785

10.  Dopamine transporter genotype and stimulant side effect factors in youth diagnosed with attention-deficit/hyperactivity disorder.

Authors:  Reut Gruber; Ridha Joober; Natalie Grizenko; Bennett L Leventhal; Edwin H Cook; Mark A Stein
Journal:  J Child Adolesc Psychopharmacol       Date:  2009-06       Impact factor: 2.576

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.